Syncope in patients with transthyretin amyloid cardiomyopathy: clinical features and outcomes

References

• Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268–292.
   PubMed Web of Science ®Google Scholar
• Iadanza M, Jackson M, Hewitt E, et al. A new era for understanding amyloid structures and disease. Rev Mol Cell Biol. 2018;19:755–773.
   PubMed Web of Science ®Google Scholar
• Oerlemans M, Rutten K, Minnema M, et al. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27(11):525–536.
   PubMed Web of Science ®Google Scholar
• Barge-Caballero G, Vázquez-García R, Barge-Caballero E, et al. Light chain and transthyretin cardiac amyloidosis: clinical characteristics, natural history and prognostic factors. Med Clin (Barc). 2020; epub ahead of print. 10.1016/j.medcli.2020.04.031.
   Web of Science ®Google Scholar
• Ruberg F, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC State-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–2891.
   PubMed Web of Science ®Google Scholar
• García-Pavía P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail. 2021 Apr 7; Online ahead of print. 10.1002/ejhf.2140
   Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–1212.
   PubMed Web of Science ®Google Scholar
• Chamarthi B, Dubrey S, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997;80(9):1242–1245.
   PubMed Web of Science ®Google Scholar
• Palma J, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Autonom Res. 2019;29(S1):33–34
   PubMed Web of Science ®Google Scholar
• Donnellan E, Wazni O, Saliba W, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020;128:140–146.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Hanna M, Grogan M, et al. THAOS investigators. genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Hereditary Amyloidosis Observational Survey). J Am Coll Cardiol. 2016;68(2):161–172.
   PubMed Web of Science ®Google Scholar
• Sayed RH, Rogers D, Khan F, et al. A study of implantable cardiac rhythm recorders in advanced AL cardiac amyloidosis. Eur Heart J. 2015;36(18):1098–1105.
   PubMed Web of Science ®Google Scholar
• Linhart M, Troatz C, Nickenin G, et al. Cardiac amyloidosis presenting as recurrent syncope. Rev Esp Cardiol. 2011;64(9):840–841.
   PubMed Web of Science ®Google Scholar
• Nunes NSV, Carvalho JPM, Costa FS, et al. Syncope as a Phenotypic Expression of Hereditary Transthyretin Amyloidosis Val142Ile (Val122Ile). Arq Bras Cardiol. 2020;114(Suppl 1):1–3.
   PubMed Web of Science ®Google Scholar
• Vita G, Mazzeo A, Di Leo L, et al. Recurrent syncope as persistently isolated feature of transthyretin amyloidotic polyneuropathy. Neuromuscul Disord. 2005;15(3):259–261.
   PubMed Web of Science ®Google Scholar
• Barge-Caballero G, Barge-Caballero E, López-Pérez M, et al. Cardiac amyloidosis: description of a series of 143 cases. Med Clin (Barc). 2022 Jan;4:0025–7753(21)006722. Online ahead of print.
   Google Scholar
• Barge-Caballero G, Barge-Caballero E, López-Pérez M, et al. Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. Mayo Clin Proc. 2022;97(2):261–273.
   PubMed Web of Science ®Google Scholar
• Brignole M, Moya A, de Lange FJ, et al., ESC Scientific Document Group. ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883–1948.
   PubMed Web of Science ®Google Scholar
• Gillmore J, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806.
   PubMed Web of Science ®Google Scholar
• Soteriades E, Evans J, Larson M, et al. Incidence and prognosis of syncope. N Eng J Med. 2002;347(12):878–885.
   PubMed Web of Science ®Google Scholar
• Alpert J. Syncope in the elderly. Am J Med. 2019;132(10):1116.
   Web of Science ®Google Scholar
• López-Sainz A, Hernandez-Hernandez A, Gonzalez-Lopez E, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol. 2020; Epub ahead of print. 10.1016/j.rec.2019.12.020.
   Web of Science ®Google Scholar
• Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013 Apr 22;2(2):e000098.
   PubMed Web of Science ®Google Scholar
• Giancaterino S, Urey M, Darden D, et al. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6(4):351–361.
   PubMedGoogle Scholar
• Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rythm. 2014;11(1):158–162
   PubMed Web of Science ®Google Scholar
• Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Duarte A, Barroso F, Mundayat R, et al. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS). Auton Neurosci. 2019;222:102590.
   PubMed Web of Science ®Google Scholar
• Higgins A, Annapureddy A, Wang Y, et al. Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy. J Am Heart Assoc. 2020;9(18):e016038.
   PubMed Web of Science ®Google Scholar
• Finocchiaro G, Pinamonti B, Merlo M, et al. Focus on cardiac amyloidosis: a single-center experience with a long-term follow-up. J Cardiovasc Med (Hagerstown). 2013;14(4):281–288.
   PubMed Web of Science ®Google Scholar